Identifying problematic drugs based on the characteristics of their targets

Frontiers in Pharmacology

Volumn 6, Issue SEP, 2015, Pages

  Lopes, Tiago J S ^a,b,c   Shoemaker, Jason E ^a,c   Matsuoka, Yukiko ^a,d   Kawaoka, Yoshihiro ^a,b,c   Kitano, Hiroaki ^a,d,e,f,g  

^a JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d Systems Biology Institute   (Japan)

^e SONY COMPUTER SCIENCE LABORATORIES INC   (Japan)

^f OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY   (Japan)

^g Institute of Physical and Chemical Research   (Japan)

Author keywords

Drug safety; Machine learning; Multi target drugs; Protein networks; Supervised learning; Target validation

Indexed keywords

AMINO ACID SEQUENCE; ARTICLE; CLASSIFIER; DRUG APPROVAL; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HUMAN; MACHINE LEARNING; PERCEPTRON; PREDICTION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SEQUENCE HOMOLOGY;

EID: 84944727529     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00186     Document Type: Article

References (64)

1. Aha, D. W., Kibler, D., and Albert, M. K. (1991). Instance-based learning algorithms. Mach. Learn. 6, 37-66. doi: 10.1007/BF00153759
2. Altschul, S. F., Madden, T. L., Sch�ffer, A. A., Zhang, J., Zhang, Z., Miller, W., et al. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402. doi: 10.1093/nar/25.17.3389
3. Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., et al. (2008). Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699. doi: 10.1038/nchembio.117
4. Atkinson, H. J., Morris, J. H., Ferrin, T. E., and Babbitt, P. C. (2009). Using sequence similarity networks for visualization of relationships across diverse protein superfamilies. PLoS ONE 4:e4345. doi: 10.1371/journal.pone.0004345
5. Batista, G. E. A. P. A., Monard, M. C., and Bazzan, A. L. C. (2004). Improving rule induction precision for automated annotation by balancing skewed data sets. Knowl. Explor. Life Sci. Inform. Proc. 3303, 20-32. doi: 10.1007/978-3-540-30478-4_3
6. Bishop, C. M. (1995). Neural Networks for Pattern Recognition. Oxford; New York, NY: Clarendon Press; Oxford University Press.
7. Breiman, L. (2001). Random forests. Mach. Learn. 45, 5-32. doi: 10.1023/A:1010933404324
8. Bunnage, M. E. (2011). Getting pharmaceutical RandD back on target. Nat. Chem. Biol. 7, 335-339. doi: 10.1038/nchembio.581
9. Burt, R. S. (1992). Structural Holes: The Social Structure of Competition. Cambridge, MA: Harvard University Press.
10. Burt, R. S. (2004). Structural holes and good ideas. Am. J. Soc. 110, 349-399. doi: 10.1086/421787
11. Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., et al. (2009). BLAST+: architecture and applications. BMC Bioinformatics 10:421. doi: 10.1186/1471-2105-10-421
12. Camoglu, O., Can, T., and Singh, A. K. (2006). Integrating multi-attribute similarity networks for robust representation of the protein space. Bioinformatics 22, 1585-1592. doi: 10.1093/bioinformatics/btl130
13. Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J., and Bork, P. (2008). Drug target identification using side-effect similarity. Science 321, 263-266. doi: 10.1126/science.1158140
14. Chawla, N. V., Bowyer, K. W., Hall, L. O., and Kegelmeyer, W. P. (2002). SMOTE: Synthetic minority over-sampling technique. J. Artif. Intell. Res. 16, 321-357. doi: 10.1613/jair.953
15. Cleary, J., and Trigg, L. (1995). "K*: an instance-based learner using an entropic distance measure," in Proceedings of the 12th International Conference on Machine Learning (Morgan Kaufmann), 108-114.
16. Cohen, W. (1995). "Fast effective rule induction," in Proceedings of the Twelfth International Conference on Machine Learning (Morgan Kaufmann), 115-123.
17. Correll, C. U., Lencz, T., and Malhotra, A. K. (2011). Antipsychotic drugs and obesity. Trends Mol. Med. 17, 97-107. doi: 10.1016/j.molmed.2010.10.010
18. Cortes, C., and Vapnik, V. (1995). Support-vector networks. Mach. Learn. 20, 273-297. doi: 10.1007/BF00994018
19. Csardi, G., and Nepusz, T. (2006). The Igraph software package for complex network research. InterJournal Complex Systems, 1695. Available online at: http://www.igraph.org
20. Csermely, P., Agoston, V., and Pongor, S. (2005). The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 26, 178-182. doi: 10.1016/j.tips.2005.02.007
21. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91, 4082-4085. doi: 10.1073/pnas.91.9.4082
22. De Hert, M., Detraux, J., Van Winkel, R., Yu, W., and Correll, C. U. (2012). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 8, 114-126. doi: 10.1038/nrendo.2011.156
23. Dong, L., Frank, E., and Kramer, S. (2005). "Ensembles of balanced nested dichotomies for multi-class problems," in Proceedings of the 9th European conference on Principles and Practice of Knowledge Discovery in Databases (Porto: Springer-Verlag).
24. Evans, R., Hinds, S., and Hammock, D. (2009). Portfolio analysis and RandD decision making. Nat. Rev. Drug Discov. 8, 189-190. doi: 10.1038/nrd2744
25. Fleishman, S. J., Whitehead, T. A., Ekiert, D. C., Dreyfus, C., Corn, J. E., Strauch, E. M., et al. (2011). Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332, 816-821. doi: 10.1126/science.1202617
26. Frank, E., Hall, M., Trigg, L., Holmes, G., and Witten, I. H. (2004). Data mining in bioinformatics using Weka. Bioinformatics 20, 2479-2481. doi: 10.1093/bioinformatics/bth261
27. Frank, E., and Witten, I. H. (1998). "Generating accurate rule sets without global optimization," in Proceedings of the Fifteenth International Conference on Machine Learning (San Francisco, CA: Morgan Kaufmann Publishers Inc.), 144-151.
28. Frishman, W. H. (1988). Beta-adrenergic receptor blockers. Adverse effects and drug interactions. Hypertension 11, II21-II29.
29. Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., et al. (2012). ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107. doi: 10.1093/nar/gkr777
30. Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690. doi: 10.1038/nchembio.118
31. John, G.H., and Langley, P. (1995). "Estimating continuous distributions in Bayesian classifiers," in Proceedings of the Eleventh Conference on Uncertainty in Artificial Intelligence (Montreal, QC: Morgan Kaufmann Publishers Inc.).
32. Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., and Shoichet, B. K. (2007). Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197-206. doi: 10.1038/nbt1284
33. Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., et al. (2009). Predicting new molecular targets for known drugs. Nature 462, 175-181. doi: 10.1038/nature08506
34. Kitano, H. (2007). Towards a theory of biological robustness. Mol. Syst. Biol. 3:137. doi: 10.1038/msb4100179
35. Kola, I., and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-716. doi: 10.1038/nrd1470
36. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., and Bork, P. (2010). A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343. doi: 10.1038/msb.2009.98
37. Liu, Z., Shi, Q., Ding, D., Kelly, R., Fang, H., and Tong, W. (2011). Translating clinical findings into knowledge in drug safety evaluation-drug induced liver injury prediction system (DILIps). PLoS Comput. Biol. 7:e1002310. doi: 10.1371/journal.pcbi.1002310
38. Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., et al. (2012). Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361-367. doi: 10.1038/nature11159
39. Melville, P., and Mooney, R. J. (2003). "Constructing diverse classifier ensembles using artificial training examples," in Proceedings of the 18th International Joint Conference on Artificial Intelligence (Acapulco: Morgan Kaufmann Publishers Inc.).
40. Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968. doi: 10.1038/nrd2961
41. Quinlan, J. R. (1993). C4.5: Programs for Machine Learning. San Mateo, CA: Morgan Kaufmann Publishers.
42. Rattei, T., Tischler, P., Gotz, S., Jehl, M. A., Hoser, J., Arnold, R., et al. (2010). SIMAP-a comprehensive database of pre-calculated protein sequence similarities, domains, annotations and clusters. Nucleic Acids Res. 38, D223-D226. doi: 10.1093/nar/gkp949
43. Riss, J., Cloyd, J., Gates, J., and Collins, S. (2008). Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol. Scand. 118, 69-86. doi: 10.1111/j.1600-0404.2008.01004.x
44. Rodr�guez, J. J., and Kuncheva, L. I. (2006). Rotation forest: a new classifier ensemble method. IEEE Trans. Pattern Anal. Mach. Intell. 28, 1619-1630. doi: 10.1109/TPAMI.2006.211
45. Roodhart, J. M., Langenberg, M. H., Witteveen, E., and Voest, E. E. (2008). The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr. Clin. Pharmacol. 3, 132-143. doi: 10.2174/157488408784293705
46. Scannell, J. W., Blanckley, A., Boldon, H., and Warrington, B. (2012). Diagnosing the decline in pharmaceutical RandD efficiency. Nat. Rev. Drug Discov. 11, 191-200. doi: 10.1038/nrd3681
47. Schaefer, M. H., Fontaine, J. F., Vinayagam, A., Porras, P., Wanker, E. E., and Andrade-Navarro, M. A. (2012). HIPPIE: integrating protein interaction networks with experiment based quality scores. PLoS ONE 7:e31826. doi: 10.1371/journal.pone.0031826
48. Sing, T., Sander, O., Beerenwinkel, N., and Lengauer, T. (2005). ROCR: visualizing classifier performance in R. Bioinformatics 21, 3940-3941. doi: 10.1093/bioinformatics/bti623
49. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571. doi: 10.1056/NEJM199911183412102
50. Stephens, T. D., Bunde, C. J., and Fillmore, B. J. (2000). Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol. 59, 1489-1499. doi: 10.1016/S0006-2952(99)00388-3
51. Tomek, I. (1976). 2 Modifications of Cnn. IEEE Trans. Syst. Man Cybern. 6, 769-772. doi: 10.1109/TSMC.1976.4309452
52. Valavanis, I., Spyrou, G., and Nikita, K. (2010). A similarity network approach for the analysis and comparison of protein sequence/structure sets. J. Biomed. Inform. 43, 257-267. doi: 10.1016/j.jbi.2010.01.005
53. Venkatesan, K., Rual, J. F., Vazquez, A., Stelzl, U., Lemmens, I., Hirozane-Kishikawa, T., et al. (2009). An empirical framework for binary interactome mapping. Nat. Methods 6, 83-90. doi: 10.1038/nmeth.1280
54. Verheul, H. M. W., Panigrahy, D., Yuan, J., and D'Amato, R. J. (1999). Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br. J. Cancer 79, 114-118. doi: 10.1038/sj.bjc.6690020
55. Weston, J., Elisseeff, A., Zhou, D., Leslie, C. S., and Noble, W. S. (2004). Protein ranking: from local to global structure in the protein similarity network. Proc. Natl. Acad. Sci. U.S.A. 101, 6559-6563. doi: 10.1073/pnas.0308067101
56. Whitehead, T. A., Chevalier, A., Song, Y., Dreyfus, C., Fleishman, S. J., De Mattos, C., et al. (2012). Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat. Biotechnol. 30, 543-548. doi: 10.1038/nbt.2214
57. Wieseler, B., Wolfram, N., Mcgauran, N., Kerekes, M. F., Verv�lgyi, V., Kohlepp, P., et al. (2013). Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med. 10:e1001526. doi: 10.1371/journal.pmed.1001526
58. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., et al. (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668-D672. doi: 10.1093/nar/gkj067
59. Witten, I. H., Frank, E., and Hall, M. A. (2011). Data Mining: Practical Machine Learning Tools and Techniques. Burlington, MA: Morgan Kaufmann.
60. Xie, L., Li, J., Xie, L., and Bourne, P. E. (2009). Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of cetp inhibitors. PLoS Comput. Biol. 5:e1000387. doi: 10.1371/journal.pcbi.1000387
61. Yamanishi, Y., Araki, M., Gutteridge, A., Honda, W., and Kanehisa, M. (2008). Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24, i232-i240. doi: 10.1093/bioinformatics/btn162
62. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barab�si, A. L., and Vidal, M. (2007). Drug-target network. Nat. Biotechnol. 25, 1119-1126. doi: 10.1038/nbt1338
63. Zhang, Z., and Grigorov, M. G. (2006). Similarity networks of protein binding sites. Proteins 62, 470-478. doi: 10.1002/prot.20752
64. Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., et al. (2012). Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40, D1128-D1136. doi: 10.1093/nar/gkr797